PTC Therapeutics, Inc. Share Price & Technical Analysis
PTCT · $68.81 (-1.40%)
Healthcare / Biotechnology
$68.81
-1.40%
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervou…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
6% return in May, -5% avg return in past 3 year May month.
-8% return in 2026, 35% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -9% | 1% | -5% | 6% | – | – | – | – | – | – | – | -8% |
| 25 | -1% | 20% | -8% | -2% | -3% | 0% | 7% | -5% | 24% | 12% | 27% | -9% | 63% |
| 24 | -3% | 8% | 10% | 11% | 13% | -15% | 10% | 4% | 6% | 8% | 10% | -13% | 47% |
| 23 | 20% | -5% | 11% | 14% | -24% | -3% | -1% | -2% | -44% | -16% | 23% | 20% | -6% |
| 22 | 1% | -13% | 7% | -6% | -17% | 36% | 8% | 16% | 0% | -25% | 9% | -9% | 6% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.17B
P/E ratio
—
52W high
$87.50
52W low
$43.17
Volume
7,15,145
Beta
0.53
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is PTC Therapeutics, Inc. share price today?
- PTC Therapeutics, Inc. (PTCT) last traded around $68.81 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PTCT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PTCT. Download the app for real-time alerts.
- How can I analyze PTC Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.